International Journal of Clinical Research
International Journal of Clinical Research. 2023; 7: (4) ; 10.12208/j.ijcr.20230156 .
总浏览量: 230
1 陕西中医药大学第二临床医学院 陕西咸阳
2 陕西中医药大学第二附属医院 陕西咸阳
3 西安市人民医院／西安市第四医院生殖医学中心 陕西西安
*通讯作者： 赵静,单位： 西安市人民医院／西安市第四医院生殖医学中心 陕西西安；
目的 开发并验证一种基于坏死性凋亡相关的IncRNA预后模型，旨在探讨坏死性凋亡相关lncRNA在子宫内膜癌中的潜在预后价值及其与子宫内膜癌（EC）免疫微环境和治疗反应的关系。方法 从癌症基因组图谱（TCGA）（https://portal.gdc.cancer.gov）下载子宫内膜癌患者的转录组数据和临床数据。通过Pearson相关分析鉴定坏死性凋亡相关的lncRNA。采用单因素Cox和多因素Cox回归分析、LASSO回归构建坏死性凋亡相关IncRNA模型。采用Kaplan-Meier分析、受试者工作特征（ROC）曲线、列线图和校准曲线来验证该模型。最后进行了基因集富集分析（GSEA）、免疫分析和药物敏感性分析。结果 基于坏死性凋亡相关基因鉴定出377个在正常和子宫内膜癌样本之间差异表达的lncRNA。通过Cox回归分析和LASSO回归建立了由9种坏死性凋亡相关lncRNA（AL021578.1、CDKN2B-AS1、AL137003.1、UNQ6494、AC064801.1、AC027319.1、AC244517.7、LINC00942、AL031770.1）组成的预后风险模型。根据这一模型，子宫内膜癌患者被分为低风险组和高风险组。Cox 回归证实该特征为独立的预后预测因子，AUC值为0.729，用于预测患者1年的总生存期（OS）。然后建立临床特征（包括年龄和病理分级）的列线图及校准图，校准图用来验证列线图与模型中1年、3年和5年生存期的预测具有良好的一致性。此外，GSEA分析表明，与癌症相关的信号通路被富集在低危组；免疫分析显示，大多数免疫细胞、ESTIMAT 评分和免疫评分均与风险评分呈负相关，低风险组免疫检查点基因的表达更高。此外，低风险组患者对司美替尼、塞来昔布、来他替尼、阿糖胞苷、二甲双胍等药物的敏感性更高。结论 基于9种坏死性凋亡相关的lncRNA，建立了一个可以用来预测子宫内膜癌患者的预后、肿瘤免疫微环境及治疗反应的模型。靶向这些lncRNA将是全身治疗失败的另外一种新方法。因此，IncRNA、坏死性凋亡和子宫内膜癌之间的分子机制值得研究。
Objetive To develop and validate a prognostic model based on necroptosis-associated IncRNA, aiming to explore the potential prognostic value of necroptosis-associated lncRNA in endometrial cancer and its relationship with the immune microenvironment and treatment response in endometrial cancer (EC). Methods Transcriptomic and clinical data of endometrial cancer patients were downloaded from The Cancer Genome Atlas (TCGA) (https://portal.gdc.cancer.gov). Necroptosis-associated lncRNAs were identified by Pearson correlation analysis. one-way Cox and multi-way Cox regression analysis, and LASSO regression were used to construct necroptosis-associated IncRNA models. Kaplan-Meier analysis, subject operating characteristic (ROC) curves, column line plots and calibration curves were used to validate the model. Finally, gene set enrichment analysis (GSEA), immunoassay and drug sensitivity analysis were performed. Results 377 lncRNAs differentially expressed between normal and endometrial cancer samples were identified based on necroptosis-associated genes. lncRNAs were established by Cox regression analysis and LASSO regression consisting of nine necroptosis-associated lncRNAs (AL021578.1, CDKN2B-AS1, AL137003.1, UNQ6494 AC064801.1, AC027319.1, AC244517.7, LINC00942, AL031770.1) as a prognostic risk model. According to this model, patients with endometrial cancer were divided into low- and high-risk groups. cox regression confirmed this feature as an independent prognostic predictor with an AUC value of 0.729 for predicting patients' overall survival (OS) at 1 year. Columnar plots of clinical characteristics (including age and pathological grading) and calibration plots were then created, and calibration plots were used to verify that the columnar plots were in good agreement with the predictions of 1-year, 3-year, and 5-year survival in the model. In addition, GSEA analysis showed that signaling pathways associated with cancer were enriched in the low-risk group; immune analysis showed that most immune cells, ESTIMAT score and immune score were negatively correlated with risk score, and the expression of immune checkpoint genes was higher in the low-risk group. In addition, patients in the low-risk group were more sensitive to drugs such as semitinib, celecoxib, leptatinib, cytarabine, and metformin. Conclusion s Based on nine necroptosis-associated lncRNAs, a model was developed that can be used to predict prognosis, tumor immune microenvironment, and treatment response in patients with endometrial cancer. Targeting these lncRNAs would be an additional novel approach to systemic treatment failure. Therefore, the molecular mechanisms between IncRNAs, necroptosis and endometrial cancer deserve to be investigated.
[1] LIU J, YIN J, WANG Y, et al. A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma [J]. Biol Proced Online, 2022, 24（1）: 9.
[2] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021 [J]. CA: a cancer journal for clinicians, 2021, 71（1）: 7-33.
[3] DE BOER S M, POWELL M E, MILESHKIN L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer （PORTEC-3）: final results of an international, open-label, multicentre, randomised, phase 3 trial [J]. Lancet Oncol, 2018, 19（3）: 295-309.
[4] YAN J, WAN P, CHOKSI S, et al. Necroptosis and tumor progression [J]. Trends Cancer, 2022, 8（1）: 21-7.
[5] FULDA S. Therapeutic exploitation of necroptosis for cancer therapy [J]. Semin Cell Dev Biol, 2014, 35: 51-6.
[6] ZHU Y, WANG S, XI X, et al. Integrative analysis of long extracellular RNAs reveals a detection panel of noncoding RNAs for liver cancer [J]. Theranostics, 2021, 11（1）: 181-93.
[7] JIANG N, ZHANG X, GU X, et al. Progress in understanding the role of lncRNA in programmed cell death [J]. Cell Death Discov, 2021, 7（1）: 30.
[8] HE Y B, FANG L W, HU D, et al. Necroptosis-associated long noncoding RNAs can predict prognosis and differentiate between cold and hot tumors in ovarian cancer [J]. Front Oncol, 2022, 12: 967207.
[9] HARARI-STEINFELD R, GEFEN M, SIMERZIN A, et al. The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD [J]. Cancers （Basel）, 2021, 13（3）.
[10] ZHAO Z, LIU H, ZHOU X, et al. Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer [J]. J Oncol, 2021, 2021: 6718443.
[11] GEELEHER P, COX N J, HUANG R S. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines [J]. Genome Biol, 2014, 15（3）: R47.
[12] HONG W, LIANG L, GU Y, et al. Immune-Related lncRNA to Construct Novel Signature and Predict the Immune Landscape of Human Hepatocellular Carcinoma [J]. Mol Ther Nucleic Acids, 2020, 22: 937-47.
[13] ZHAO L, FU X, HAN X, et al. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma [J]. Cancer Cell Int, 2021, 21（1）: 80.
[14] LIU L, FAN J, AI G, et al. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells [J]. Biol Res, 2019, 52（1）: 37.
[15] SUI J, LI Y H, ZHANG Y Q, et al. Integrated analysis of long non-coding RNAassociated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma [J]. Int J Oncol, 2016, 49（5）: 2023-36.
[16] LIANG D, HU M, TANG Q, et al. Nine Pyroptosis-Related lncRNAs are Identified as Biomarkers for Predicting the Prognosis and Immunotherapy of Endometrial Carcinoma [J]. Int J Gen Med, 2021, 14: 8073-85.
[17] ZHU Y, ZHOU B, HU X, et al. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability [J]. Clin Transl Med, 2022, 12（1）: e703.
[18] NAIR R, WESTIN J. CAR T-Cells [J]. Adv Exp Med Biol, 2020, 1244: 215-33.
[19] LIANG L, ZHU Y, LI J, et al. Immune Subtypes and Immune Landscape Analysis of Endometrial Carcinoma [J]. J Immunol, 2022, 209（8）: 1606-14.
[20] GUAN J, CHEN X J. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer [J]. Front Endocrinol （Lausanne）, 2022, 13: 1041535.
[21] LEE T Y, MARTINEZ-OUTSCHOORN U E, SCHILDER R J, et al. Metformin as a Therapeutic Target in Endometrial Cancers [J]. Front Oncol, 2018, 8: 341.
[22] MEIRELES C G, PEREIRA S A, VALADARES L P, et al. Effects of metformin on endometrial cancer: Systematic review and meta-analysis [J]. Gynecol Oncol, 2017, 147（1）: 167-80.
[23] KE L N, KONG L Q, XU H H, et al. Research Progress on Structure and Anti-Gynecological Malignant Tumor of Shikonin [J]. Front Chem, 2022, 10: 935894.
[24] 黄彩梅, 夏亦冬, 胡国华. 紫草素对子宫内膜癌Ishikawa细胞雌激素信号通路表达的影响 [J]. 世界中医药, 2016, 11（9）: 1842-5.
[25] 余思云, 黄彩梅, 胡国华. 紫草素通过PI3K/Akt信号通路诱导子宫内膜癌Ishikawa细胞凋亡 [J]. 世界中西医结合杂志, 2014, 9（12）: 1303-6.